natgillin/translations-raw huggingface dataset:
Forhøjet tåresekretion (G3/4: 0 %).
Lacrimation increased (G3/4: 0%)
Forhøjet urin-stof- niveau i blodet
Blood urea increased
Forhøjet urinkvælstof, alkaliske fosfataser, positiv Coombs test, leukocytter og bakterier i urinen
Elevated urea nitrogen, alkaline phosphatases; positive Coomb’s test; leucocytes, and bacteria in the urine
forhøjet urinstof - (produceres af nyrerne) – vist ved prøver
increase in “urea” - produced by the kidneys - shown in tests
Forhøjet urinstof i
Blood urea
Forhøjet urinsyre i blodet
Blood uric acid
Forhøjet urinsyre i blodet
Blood uric acid increased Blood lactate dehydrogenase
forhøjet urinsyre i blodet
increased uric acid in the blood
Forhøjet urinsyre i blodet er set i studier hos patienter med urinsyregigt i udbrud.
Increases in blood uric acid levels were observed in studies on gouty arthritis patients flaring.
Forhøjet urinsyre i blodet*
Blood uric acid increased
forhøjet urinsyre i blodet;
increased uric acid in the blood;
forhøjet urinsyre,
uric acid increased,
forhøjet urinsyreniveau i blodet
blood uric acid increased
Forhøjet urinsyreniveau i blodet
High uric acid levels in the blood;
Forhøjet γGT (især ved kombination med carbamazepin og valproat).
Raised γGT (notably when combined with carbamazepine and valproate).
Forhøjet γGT (isζr ved kombination med carbamazepin og valproat).
Raised γGT (notably when combined with carbamazepine and valproate).
Forhøjetbilirubin i blodet
Blood bilirubin increased
Forhør dig hos din læge og følg den anbefalede varighed af behandlingen.
Please check with your doctor and follow the recommended duration of treatment.
Foringsfilm
Backing film
Forkert anvendelse af overførselsanordningen vil resultere i tab af vakuum og hindre overførslen af solvens, hvilket forlænger eller hindrer opløsningen af Respreeza.
Incorrect use of the transfer device will result in loss of vacuum and prevent transfer of the solvent, thereby prolonging or preventing reconstitution of Respreeza.
Forkert brug af lægemidlet og doseringsfejl med rivastigmin depotplaster har resulteret i alvorlige bivirkninger, nogle tilfælde har krævet hospitalsindlæggelse og i sjældne tilfælde ført til dødsfald (se pkt.
Misuse of the medicinal product and dosing errors with rivastigmine transdermal patches have resulted in serious adverse reactions; some cases have required hospitalisation, and rarely led to death (see section 4.9).
Forkert brug og misbrug
Misuse and abuse
Forkert dosering af methotrexat kan medføre alvorlige bivirkninger, herunder bivirkninger med dødeligt forløb.
Faulty dosing of methotrexate may lead to serious adverse effects including fatal course.
forklarer, hvordan leukaferesen foregår forklarer, hvad Provenge-behandlingen går ud på.
The Provenge treatment process
Forklaring af symboler
Explanation of symbols
Forklaring af, hvad fotodynamisk terapi er.
What photodynamic therapy is
Forklaring angående den ikke kendte risiko for neuropati ved længerevarende brug
Explanation of unknown risk of neuropathy with long term use
Forklaring angående risikoen for neuropati ved længerevarende brug.
Explanation of risk of neuropathy with long term use
Forkortelse: CI = konfidensinterval
Abbreviation: CI = confidence interval
Forkortelse: CI = konfidensinterval
Abbreviation: CI = confidence interval.
Forkortelser: ALAT = alanin-aminotransferase; ASAT = aspartat-aminotransferase; CTCAE = Common Terminology Criteria for Adverse Event; NCI = National Cancer Institute.
Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; CTCAE = Common Terminology Criteria for Adverse Event; NCI = National Cancer Institute; SGOT = serum glutamic oxaloacectic aminotransferase; SGPT = serum glutamic pyruvic aminotransferase
Forkortelser: ALAT = alanin-aminotransferase; ASAT = aspartat-aminotransferase; CTCAE = Common Terminology Criteria for Adverse Event; NCI = National Cancer Institute.
Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; CTCAE = Common Terminology Criteria for Adverse Event; NCI = National Cancer Institute; SGOT = serum glutamic oxaloacectic aminotransferase; SGPT = serum glutamic pyruvic aminotransferase.
Forkortelser: ALAT = alanin-aminotransferase; ASAT = aspartat-aminotransferase; CTCAE = Common Terminology Criteria for Adverse Event; NCI = National Cancer Institute.
Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; CTCAE = Common Terminology Criteria for Adverse Event; NCI = National Cancer Institute; SGOT = serum glutamic oxaloacetic aminotransferase; SGPT = serum glutamic pyruvic aminotransferase.
Forkortelser: ALAT = alanin-aminotransferase; ASAT = aspartat-aminotransferase; CTCAE = Common Terminology Criteria for Adverse Event; NCI = National Cancer Institute.
Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; CTCAE = Common Terminology Criteria for Adverse Event; NCI = National Cancer Institute; SGOT=serum glutamic oxaloacectic aminotransferase; SGPT=serum glutamic pyruvic aminotransferase.
Forkortelser: ALAT = alaninaminotransferase; ASAT = aspartataminotransferase; CTCAE = Common Terminology Criteria for Adverse Event; NCI = National Cancer Institute.
Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; CTCAE = Common Terminology Criteria for Adverse Event; NCI = National Cancer Institute; SGOT = serum glutamic oxaloacetic aminotransferase; SGPT = serum glutamic pyruvic aminotransferase.
Forkortelser: ASAT = aspartat-aminotransferase, ULN = øvre grænse for normalområdet.
Abbreviations: SGOT=serum glutamic oxaloacetic transaminase; AST=aspartate aminotransferase; ULN=upper limit of the normal range.
Forkortelser: AUCt = areal under plasmakoncentrations-tids-kurven fra nul til sidste målbare koncentration; t1/2 = halveringstid; CL = clearance; FVIII:C = FVIII-aktivitet; MRT = middel residenstid
Abbreviations: AUCt = area under the plasma concentration-time curve from zero to the last measurable concentration; t½ = half-life; CL = clearance; FVIII:C = FVIII activity; MRT = mean residence time
Forkortelser: CGI-C: clinical global impression of change from baseline (klinisk globalt indtryk af ændring i forhold til baseline); CI: confidence interval (konfidensinterval); IR: immediate release (øjeblikkelig udløsning); LCE: levodopa/carbidopa/entacapon; L-dopa†: Levodopa/Carbidopa; LS: least squares (mindste kvadrater); PD: Parkinsons sygdom; SD: standard deviation (standardafvigelse); I/A: ikke relevant; t: timer; år: år.
Abbreviations: CGI-C: clinical global impression of change from baseline; CI: confidence interval; IR: immediate release; LCE: Levodopa/Carbidopa/Entacapone; L-dopa†: Levodopa/Carbidopa; LS: least squares; PD: Parkinson’s disease; SD: standard deviation; N/A: not available; hrs: hours; yrs: years.
Forkortelser: CI = konfidensinterval
Abbreviations: CI = confidence interval
Forkortelser: CI = konfidensinterval, AUC = arealet under tidskurven over FVIII-aktivitet, t½ = terminal halveringstid,
Abbreviations: CI = confidence interval; AUC = area under the FVIII activity time curve; t½ = terminal half- life;
Forkortelser: CI = konfidensinterval, Cmax= maksimal aktivitet, AUC = areal under tid-FIX-aktivitetskurven, t½= terminal halveringstid, t½α = fordelingshalveringstid, t½β = eliminationshalveringstid, CL = clearance, Vss = fordelingsvolumen ved steady state, MRT = gennemsnitlig residenstid.
Abbreviations: CI = confidence interval; Cmax= maximum activity; AUC = area under the FIX activity time curve; t1/2 = terminal half-life; t½α = distribution half-life; t½β = elimination half-life; CL = clearance; Vss = volume of distribution at steady-state; MRT = mean residence time.
Forkortelser: CI = konfidensinterval, Cmax= maksimal aktivitet, AUC = areal under tidskurven over FVIII- aktivitet, t½= terminal halveringstid, CL = clearance, Vss = fordelingsvolumen ved steady-state, MRT = mean residence time.
Abbreviations: CI = confidence interval; Cmax= maximum activity; AUC = area under the FVIII activity time curve; t½= terminal half-life; CL = clearance; Vss = volume of distribution at steady-state; MRT = mean residence time.
Forkortelser: CI = konfidensinterval, DVT = dyb venetrombose, mITT = modificeret intention-to- treat, HR = Hazard Ratio vs. warfarin, n = antal personer med hændelser, N = antal personer i mITT- population, LE = lungeemboli, VTE = venøse tromboemboliske hændelser. a Det primære endepunkt for virkning er adjudikeret symptomatisk, recidiverende VTE (det vil sige det sammensatte endepunkt med DVT, ikke-dødelig LE og dødelig LE). b Det tosidede CI for HR er baseret på Cox proportional hazards-regressionsmodellen, der inkluderer behandling og følgende stratificeringsfaktorer for randomisering som kovarianser: foreliggende diagnose (LE med eller uden DVT, kun DVT), risikofaktorer ved baseline (midlertidige faktorer, alle andre) og behovet for 30 mg edoxaban/edoxaban placebo-dosis ved randomisering (ja/nej). c p-værdien er for den prædefinerede non-inferioritetsmargin på 1,5.
Abbreviations: CI = Confidence Interval; DVT = deep vein thrombosis; mITT = modified intent-to- treat; HR = Hazard Ratio vs. warfarin; n = number of subjects with events; N = number of subjects in mITT population; PE = pulmonary embolism; VTE = venous thromboembolic events. a The primary efficacy endpoint is adjudicated symptomatic recurrent VTE (i.e., the composite endpoint of DVT, non-fatal PE, and fatal PE). b The HR, two-sided CI are based on the Cox proportional hazards regression model including treatment and the following randomisation stratification factors as covariates: presenting diagnosis (PE with or without DVT, DVT only), baseline risk factors (temporary factors, all others), and the need for 30 mg edoxaban/edoxaban placebo dose at randomisation (yes/no). c The p-value is for the pre-defined non-inferiority margin of 1.5.
Forkortelser: CI = konfidensinterval.
Abbreviations: CI = confidence interval
Forkortelser: CI = konfidensinterval; HR = risikorate (hazard ratio); IRR = uafhængig radiologisk gennemgang (Independent Radiology Review; N/n = antal patienter; NR = ikke nået (not reached); PFS = progressionsfri overlevelse (Progression-free Survival); OS = samlet overlevelse (Overall Survival).
Abbreviations: CI=confidence interval; HR=hazard ratio; IRR=independent radiology review; N/n=number of patients; NR=not reached; PFS=progression-free survival; OS=overall survival.
Forkortelser: CI = konfidensinterval; I/R = ikke relevant.
Abbreviations: CI = confidence interval; NA = not applicable.
Forkortelser: CI = konfidensinterval; ITT = intent-to-treat; N = samlet populationsstørrelse. a Statistisk signifikans for non-inferioritet med hele konfidensintervallet for HR pænt under 1,17645 for non-inferioritet- margin (p < 0,001).
Abbreviations: CI = confidence interval; ITT = intent-to-treat; N = total population size a Statistically significant for noninferiority, with the entire confidence interval for HR well below the 1.17645 noninferiority margin (p < 0.001)
Forkortelser: CI = konfidensinterval; ITT = intent-to-treat; n = samlet populationsstørrelse. a Statistisk signifikans for non-inferioritet med hele konfidensintervallet for HR pænt under 1,17645 for noninferiøritet-margin (p <0,001).
Abbreviations: CI = confidence interval; ITT = intent-to-treat; N = total population size. aStatistically significant for noninferiority, with the entire confidence interval for HR well below the 1.17645 noninferiority margin (p <0.001).
Forkortelser: CI = konfidensinterval; ITT = Intent-To-Treat; n = samlet populationsstørrelse. a Statistisk signifikans for non-inferioritet, med hele konfidensintervallet for HR pænt under 1,17645 marginen for noninferioritet (p <0,001).
Abbreviations: CI = confidence interval; ITT = intent-to-treat; N = total population size. a Statistically significant for noninferiority, with the entire confidence interval for HR well below the 1.17645 noninferiority margin (p <0.001).
Forkortelser: CI = konfidensinterval; ITT = intent-to-treat; N = samlet populationsstørrelse. a Statistisk signifikans for non-inferiøritet med hele konfidensintervallet for HR pænt under 1,17645 for non- inferiøritet-margin (p <0,001).
Abbreviations: CI = confidence interval; ITT = intent-to-treat; N = total population size. a Statistically significant for noninferiority, with the entire confidence interval for HR well below the 1.17645 noninferiority margin (p < 0.001).
Forkortelser: CI = konfidensinterval; ITT = intent-to-treat; N = samlet populationsstørrelse. a Statistisk signifikans for non-inferiøritet med hele konfidensintervallet for HR pænt under 1,17645 for non- inferiøritet-margin (p <0,001).
Abbreviations: CI = confidence interval; ITT = intent-to-treat; N = total population size. a Statistically significant for noninferiority, with the entire confidence interval for HR well below the 1.17645 noninferiority margin (p <0.001).
Forkortelser: CI = konfidensinterval; ITT = intent-to-treat; N = samlet populationsstørrelse. a Statistisk signifikans for non-inferiøritet, med hele konfidensintervallet for HR pænt under 1.17645 for non- inferiøritet margin (p <0,001).
Abbreviations: CI = confidence interval; ITT = intent-to-treat; N = total population size. a Statistically significant for noninferiority, with the entire confidence interval for HR well below the 1.17645 noninferiority margin (p < 0.001).
Forkortelser: CI = konfidensinterval; ITT = intent-to-treat; N = samlet populationsstørrelse. a Statistisk signifikans for non-inferiøritet, med hele konfidensintervallet for HR pænt under 1.17645 for non- inferiøritet margin (p <0,001).
Abbreviations: CI = confidence interval; ITT = intent-to-treat; N = total population size. a Statistically significant for noninferiority, with the entire confidence interval for HR well below the 1.17645 noninferiority margin (p <0.001).
Forkortelser: CI: konfidensinterval, DTIC: dacarbazin, HR: hazard ratio. aDefineret som komplet respons + partiel respons.
Abbreviations: CI: confidence interval; DTIC: dacarbazine; HR: hazard ratio; NR: not reached a Defined as confirmed complete +partial response.
Forkortelser: CI: konfidensinterval; NR: ikke nået; NA: ikke relevent a – Bekræftet respons. b – Dette studie var designet til at underbygge eller forkaste nul-hypotesen om OIRR ≤ 10 % (baseret på historiske resultater), til fordel for den anden hypotese om, at OIRR ≥ 30 % i BRAF V600E mutationspositive patienter.
Abbreviations: CI: confidence interval; NR: not reached; NA: not applicable a Confirmed response. b This study was designed to support or reject the null hypothesis of OIRR ≤10% (based on historical results) in favour of the alternative hypothesis of OIRR ≥ 30% in BRAF V600E mutation positive subjects.
Forkortelser: CI=konfidensinterval, N=antal patienter, NR=ikke nået.
Abbreviations: CI=confidence interval; N=number of patients; NR=not reached.
Forkortelser: CLL= kronisk, lymfatisk leukæmi, CR= komplet respons, IRC= Independent Review Committee, MRD= Minimal Residue Disease, N= antal, ORR= overordnet responsrate.
Abbreviations: CI = confidence interval, CLL = Chronic Lymphocytic Leukemia, CR = Complete Response, IRC = Independent Review Committee, MRD = Minimal Residue Disease, N = number, ORR = Overall Response Rate
Forkortelser: ICH = intrakraniel blødning, HR = Hazard Ratio vs. warfarin, CI = konfidensinterval, N = antallet af personer i sikkerhedspopulationer, n = antal hændelser, CRNM = klinisk relevant ikke svær
Abbreviations: ICH = Intracranial Haemorrhage, HR = Hazard Ratio vs. warfarin; CI = Confidence Interval; N = number of subjects in safety population; n = number of events; CRNM = clinically relevant non-major
Forkortelser: KI = konfidensinterval
Abbreviations: CI = confidence interval
Forkortelser: KI = konfidensinterval, CR= komplet respons, PR= partiel respons, CMH= Cochran- Mantel-Haenszel
Abbreviations: CI = confidence interval, CR= complete response, PR= partial response, CMH = Cochran-Mantel-Haenszel
Forkortelser: KI = konfidensinterval, CR= komplet respons, PR= partiel respons, CMH= Cochran- Mantel-Haenszel
Abbreviations: CI = confidence interval, CR= complete response, PR= partial response, CMH= Cochran-Mantel-Haenszel
Forkortelser: MCyR = major cytogenetisk respons, Resp=respondenter, Eval = evaluerbare.
Abbreviations: MCyR = Major Cytogenetic Response, Resp = responders, Eval = evaluable.
Forkortelser: N = antal patienter randomiseret til hver behandlingsgruppe; KI = konfidensinterval
Abbreviations: N = number of patients randomly assigned to each treatment group; CI = Confidence Interval.
Forkortelser: N = antal personer mITT-population samlet studieperiode, n = antal patienter i undergruppen
Abbreviations: N = number of subjects; mITT population overall study period; n = number of patients in subgroup
Forkortelser: N = antal personer, mITT-population samlet studieperiode, n = antal patienter i undergruppen
Abbreviations: N = number of subjects; mITT population overall study period; n = number of patients in subgroup
Forkortelser: n/a= ikke tilgængelig; CI=konfidensinterval; CCyR=komplet cytogenetisk respons; MMR=major molekylært respons; CMR=komplet molekylært respons; IS=International skala.
Abbreviations: n/a = not available, CI = Confidence Interval; CCyR = Complete Cytogenetic Response; MMR = Major Molecular Response, CMR = Complete Molecular Response, IS=International Scale.
Forkortelser: NA, ikke tilgængelig; ORR: samlet responsrate; CR: fuldstændigt respons; PR: partielt respons
Abbreviations: NA, not available; ORR: overall response rate; CR: complete response; PR: partial response
Forkortelser: NA, ikke tilgængelig; ORR: samlet responsrate; CR: fuldstændigt respons; PR: partielt respons.
Abbreviations: NA, not available; ORR: overall response rate; CR: complete response; PR: partial response
Forkortelser: PFS, progressionsfri overlevelse; Dox, doxorubicin; Epi, epirubicin; Relativ risiko, komparator taget som reference; Risikoforholdstal, Myocet taget som reference. a Sekundært endpoint
Abbreviations: PFS, progression-free survival; Dox, doxorubicin; Epi, epirubicin; Relative Risk, comparator taken as reference; Risk Ratio, Myocet taken as reference a Secondary endpoint
Forkortelser: QD: én gang dagligt; BID: to gange dagligt
Abbreviations: QD: once daily; BID: twice daily
Forkortelser: β2M= Beta-2-microglobulin, CIRS-G= Cumulative Illness Rating Scale for Geriatrics, CLL= kronisk, lymfatisk leukæmi, CrCl= kreatininclearance, ECOG= Eastern Cooperative Oncology Group, IGHV= Immunoglobulin Heavy Chain Variable Region, IRC= Independent Review Committee, N= antal, IN= Ikke nået, PFS= Progressionsfri overlevelse, ZAP-70= Zeta-Chain- associated proteinkinase 70.
Abbreviations: β2M = Beta-2-microglobulin, CI = confidence interval, CIRS-G = Cumulative Illness Rating Scale for Geriatrics, CLL = Chronic Lymphocytic Leukemia, CrCl = Creatinine Clearance, ECOG = Eastern Cooperative Oncology Group, IGHV = Immunoglobulin Heavy Chain Variable Region, IRC = Independent Review Committee, N = number, NR = Not Reached, PFS = Progression-free Survival, ZAP-70 = Zeta-Chain- associated protein kinase 70.
Forkortelser: β2M= Beta-2-microglobulin, CIRS-G= Cumulative Illness Rating Scale for Geriatrics, CLL= kronisk, lymfatisk leukæmi, CrCl= kreatininclearance, ECOG= Eastern Cooperative Oncology Group, IGHV= Immunoglobulin Heavy Chain Variable Region, IRC= Independent Review Committee, N= antal, IN= Ikke nået, PFS= Progressionsfri overlevelse, ZAP-70= Zeta-kæde- associeret proteinkinase 70.
Abbreviations: β2M = Beta-2-microglobulin, CI = confidence interval; CIRS-G = Cumulative Illness Rating Scale for Geriatrics, CLL = Chronic Lymphocytic Leukemia, CrCl = Creatinine Clearance, ECOG = Eastern Cooperative Oncology Group, IGHV = Immunoglobulin Heavy Chain Variable Region, IRC = Independent Review Committee, N = number, NR = Not Reached, PFS = Progression-free Survival, ZAP-70 = Zeta-Chain- associated protein kinase 70.
Forkortelser:  = Stigning;  = Fald;  = Ingen signifikant ændring; AUC = Arealet under kurven koncentration versus tid; Cmax= Maksimal observeret koncentration; CL/F = Tilsyneladende oral clearance.
Abbreviations:  = Increase;  = decrease;  = no significant change; AUC = area under the concentration versus time curve; Cmax = maximum observed concentration; CL/F = apparent oral clearance
Forkortelser:  = Stigning;  = Fald;  = Ingen signifikant ændring; AUC = Arealet under kurven koncentration versus tid; Cmax= Maksimalt observeret koncentration; CL/F = Tilsyneladende oral clearance
Abbreviations:  = Increase; =decrease; = no significant change; AUC=area under the concentration versus time curve; Cmax=maximum observed concentration; CL/F=apparent oral clearance
Forkortelser:  = Stigning;  = Fald;  = Ingen signifikant ændring; AUC = Arealet under kurven koncentration versus tid; Cmax= Maksimalt observeret koncentration; CL/F = Tilsyneladende oral clearance.
Abbreviations:  = Increase; =decrease; = no significant change; AUC=area under the concentration versus time curve; Cmax=maximum observed concentration; CL/F=apparent oral clearance
Forkølelse
Common cold
Forkølelse
Common cold (nasopharyngitis)
Forkølelse
Nasopharyngitis
forkølelse (nasofaryngitis) hoste
nasopharyngitis (cold) cough
Forkølelse (øvre luftvejsinfektion)
Cold (upper respiratory tract infection)
forkølelse eller influenza
a cold or the flu
forkølelse eller influenzalignende symptomer som ondt i halsen og tilstoppet næse
Cold or flu-like symptoms such as sore throat, stuffy or blocked nose
Forkølelse*
common cold
Forkølelse, for eksempel næsen løber, ondt i halsen eller bihulebetændelse (nasofaryngitis eller infektioner i øvre luftveje)
Common cold, such as runny nose, sore throat or sinus infections (nasopharyngitis or upper respiratory tract infections)
Forkølelsessymptomer
Common cold symptoms
forkølelsessymptomer som ondt i halsen og tilstoppet næse
Cold like symptoms such as sore throat, stuffy or blocked nose,
forkølelsessymptomer som ondt i halsen, tilstoppet næse, træthed, feber, kulderystelser og tør hoste
Cold symptoms such as sore throat, stuffy or blocked nose, feeling tired, fever, chills, dry cough
forkølelsessymptomer, urinvejsinfektion, influenza-lignende symptomer.
common cold symptoms, urinary tract infection, feeling like you have the flu
forkølelsessår
cold sores
forkølelsessår (oral herpes simplex), blistre
cold sores (oral herpes simplex), blisters
forkølelsessår (oral herpes)
cold sores (oral herpes)
forkølelsessår eller andet herpesudbrud
cold sores or other herpes infections
forkølelsessår eller andet herpesudbrud,
cold sores or other herpes infections
forkølelsessår eller andre herpesinfektioner
cold sores or other herpes infections
Forligelig dosiskoncentration
Incompatible concentrations
Forligelige infusionsvæsker til i.v.-drop
IV line solution compatibility
Forligelige intravenøse opløsninger omfatter: 9 mg/ml (0,9 %) natriumchlorid-injektionsvæske, 50 mg/ml (5 %) glucose-injektionsvæske og Ringer-lactat-injektionsvæske.
Compatible intravenous solutions include: sodium chloride 9 mg/ml (0.9 %) solution for injection, dextrose 50 mg/ml (5 %) solution for injection, and Lactated Ringer’s solution for injection.
Forligelighed mellem glas- injektionssprøjten og intravenøs adgang bør derfor sikres før anvendelse.
Therefore, the compatibility of the glass syringe and intravenous access should be ensured before use.
Forligelighed ved i.v.-drop
Administration other than IV or IM
Forligelighed ved i.v.-drop
IV line solution compatibility
Forligelighed ved i.v.-drop
Package leaflet: Information for the user
Forlæng hjertefrekvens-monitorering på sygehus mindst natten over, og indtil tilstanden er ophørt, hos patienter:
Extend heart rate monitoring for at least overnight in a medical facility and until resolution of findings in patients:
Forlæng monitorering af hjertefrekvens mindst natten over på sygehus, og indtil tilstanden er ophørt, hos patienter, som har krævet farmakologisk intervention under monitoreringen ved behandlingsstart/genoptagelse.
Extend heart rate monitoring for at least overnight in a medical facility and until resolution of findings in patients requiring pharmacological intervention during monitoring at treatment initiation/re-initiation.
forlænge den sedative virkning.
a prolonged sedative effect.